Código QR (código de barras bidimensional)

Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial

BackgroundThe optimal sequencing of CDK4/6 inhibitors combined with endocrine therapy for advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer remains uncertain, particularly in resource-limited settings such as China. This study evaluated the cost-effectiveness of first-line...

תיאור מלא

שמור ב:
Principais autores: Xiaohu Jin, Zhifeng Li
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2025-11-01
סדרה:Frontiers in Pharmacology
נושאים:
cost-effectiveness analysis
CDK4/6 inhibitors
endocrine therapy
HR+/HER2- breast cancer
SONIA
גישה מקוונת:https://www.frontiersin.org/articles/10.3389/fphar.2025.1700291/full
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים